Clinical trials are research studies with volunteer patients to help identify safe and effective treatments. This research empowers people living with the disease help to find the treatments, prevention, and ultimately, the cure for Alzheimer’s and other neurodegenerative diseases.  Dr. Crane believes in providing access to the trials, and the hope it offers patients, their families, and future generations.  

Current Clinical Trials

AriBio – “A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center, Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease” 

  • Protocol Number: AR1001-ADP3-US01

Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) 

  • Sponsored by: Alzheimer’s Association
  • Managed by: American College of Radiology

UT Collaboration and Innovation on Detection, Care, and Treatment of Alzheimer’s Disease and Related Dementia, University of Tennessee 

  • Dr. Xiaopeng Zhao and Dr. Crane

A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)

  • Universal Trial Number: U1111-1259-2920
  • EudraCT Number: 2020-004864-25
  • IND Number: 146391

New IDEAS Study

  • An observational, open-label, longitudinal cohort study designed to address the the CED provisions of the NCD on beta-amyloid PET. New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.
  • ClinicalTrials.gov Identifier: NCT04426539

A Phase 3b Multicenter, Randomized Double-blind, placebo controlled Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects with Neuropsychiatric Symptoms Related to Neurogenerative Disease 

  • Protocol Number: ACP-103-046
  • EudraCT Number: 2017-003536-36

52-week open-label extension study of Pimavanserin in Adult and Elderly Subjects with Neuropsychiatric Symptoms Related to Neurodegenerative Disease 

  • ACP-103-4047
  • EudraCT Number: 2017-004439-36

    ICARES AD: An Observational Study of Aducanumab in Participants With Alzheimer’s Disease in the US 

    • ClinicalTrials.gov Identifier: NCT05097131 

    Biogen – “A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Verify the Clinical Benefit or Aducanumab (BIIB037) in Participants with Alzheimer’s Disease” 

    Protocol Number: 221AD305